Literature DB >> 27666466

Juvenile myasthenia gravis in Norway: A nationwide epidemiological study.

T H Popperud1, M I Boldingh2, C Brunborg3, K W Faiz4, A T Heldal5, A H Maniaol2, K I Müller6, M Rasmussen7, K Øymar8, E Kerty9.   

Abstract

BACKGROUND: The aim of this study was to assess the incidence rate and prevalence of autoimmune myasthenia gravis (MG) among children in Norway.
METHODS: This retrospective population-based study was performed in Norway from January 2012 to December 2013. Cases of juvenile MG (JMG) with onset < 18 years were identified through searches in coding systems of electronic patient records at the 15 main hospitals in Norway from 1989 to 2013. In addition, the acetylcholine receptor antibody database at Haukeland University Hospital and the clinical nationwide MG database at Oslo University Hospital were searched for cases of JMG. Diagnosis and age at onset were verified through medical records. Incidence and prevalence rates were calculated using the Norwegian population as reference.
RESULTS: In total 63 unique JMG cases were identified. This corresponds to an average annual incidence rate of 1.6 per million. Incidence rate was stable over the study period. Prevalence of JMG was 3.6-13.8 per million. Females constituted the majority of JMG cases (55 vs 8 males). The risk of JMG was higher among females both in the postpubertal and prepubertal group (p < 0.001 and p = 0.02, respectively).
CONCLUSION: This study confirms the rarity of JMG in Norway, especially among males, and shows a stable incidence rate over the last 25 years.
Copyright © 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Frequency; Incidence; Juvenile myasthenia gravis; Prevalence

Mesh:

Substances:

Year:  2016        PMID: 27666466     DOI: 10.1016/j.ejpn.2016.09.001

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  7 in total

1.  Epidemiology of paraneoplastic neurological syndromes: a population-based study.

Authors:  Alberto Vogrig; Gian Luigi Gigli; Samantha Segatti; Elisa Corazza; Alessandro Marini; Andrea Bernardini; Francesca Valent; Martina Fabris; Francesco Curcio; Francesco Brigo; Donatella Iacono; Paolo Passadore; Michele Rana; Jérôme Honnorat; Mariarosaria Valente
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

2.  Incidence and Ocular Features of Pediatric Myasthenias.

Authors:  Sasha A Mansukhani; Erick D Bothun; Nancy N Diehl; Brian G Mohney
Journal:  Am J Ophthalmol       Date:  2019-01-14       Impact factor: 5.258

3.  Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.

Authors:  Xin Huang; Yingkai Li; Huiyu Feng; Pei Chen; Weibin Liu
Journal:  Front Neurol       Date:  2018-02-27       Impact factor: 4.003

4.  Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset.

Authors:  T H Popperud; M K Viken; E Kerty; B A Lie
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

5.  Thymectomy in Juvenile Myasthenia Gravis Is Safe Regarding Long Term Immunological Effects.

Authors:  Trine H Popperud; Kiran A Gul; Cathrine Brunborg; Richard W Olaussen; Tore G Abrahamsen; Liv T Osnes; Emila Kerty
Journal:  Front Neurol       Date:  2021-02-25       Impact factor: 4.003

Review 6.  The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review.

Authors:  Jeannine M Heckmann; Tarin A Europa; Aayesha J Soni; Melissa Nel
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

7.  Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study.

Authors:  Jingshan Chen; De-Cai Tian; Chao Zhang; Zixiao Li; Yi Zhai; Yuwen Xiu; Hongqiu Gu; Hao Li; Yongjun Wang; Fu-Dong Shi
Journal:  Lancet Reg Health West Pac       Date:  2020-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.